Exelixis (EXEL) is a publicly traded Healthcare sector company. As of July 5, 2026, EXEL trades at $55.85 with a market cap of $14.04B and a P/E ratio of 31.03. EXEL moved +3.57% today. Year to date, EXEL is +26.82%; over the trailing twelve months it is +26.07%. Its 52-week range spans $31.90 to $56.21. Analyst consensus is neutral with an average price target of $48.10. Rallies surfaces EXEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Exelixis jumps as Q1 EPS beats, $750M new buyback adds support: Exelixis shares are higher after reporting Q1 2026 results with total revenue of $610.8 million and GAAP diluted EPS of $0.79. The company also authorized an additional stock repurchase program of up to $750 million through the end of 2027 and reiterated 2026 revenue guidance of $2.525–$2.625 billion.
| Metric | Value |
|---|---|
| Price | $55.85 |
| Market Cap | $14.04B |
| P/E Ratio | 31.03 |
| EPS | $1.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $56.21 |
| 52-Week Low | $31.90 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.17B |
| Net Income | $521.27M |
| Gross Margin | 96.49% |
12 analysts cover EXEL: 0 strong buy, 4 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $48.10.